Updating results

53 results for dermatology Sort: Relevance | Date

Psoriasis

Everything NICE has said on psoriasis in an interactive flowchart

NICE Pathway Published October 2011 Last updated September 2017

Melanoma: assessment and management (NG14)

Evidence-based recommendations on assessing and managing melanoma (a type of skin cancer).

NICE guideline Published July 2015

Teledermatology: diagnosis, triage and effective care of dermatology

A pilot of teledermatology was carried out by 18 GP practices in the South Bristol Consortium (now the South Bristol Locality of Bristol

QP Case Study Published November 2012 Last updated 

Atopic eczema in under 12s: diagnosis and management (CG57)

Evidence-based recommendations on diagnosing and managing atopic eczema (dermatitis) in children under 12

Clinical guideline Published December 2007

ESNM14: Actinic keratosis: ingenol mebutate gel

Summary of the evidence on ingenol mebutate gel for actinic keratosis (solar keratosis) to inform local NHS planning and decision-making

Evidence summary Published March 2013

Abatacept for treating active psoriatic arthritis after DMARDs [ID993]

In development [GID-TA10173] Expected publication date: 25 July 2018

Technology appraisal guidance In development

Brodalumab for treating moderate to severe plaque psoriasis [ID878]

In development [GID-TA10220] Expected publication date: 30 May 2018

Technology appraisal guidance In development

Eczema

Everything NICE has said on managing atopic eczema in children up to 12 years, and treating eczema in people aged 13 years and over in an interactive flowchart

NICE Pathway Published August 2012 Last updated May 2017

ES10: Hyperhidrosis: oxybutynin

Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published March 2017

ESUOM31: Chronic urticaria: off-label doses of cetirizine

Summary of the evidence on off-label doses of cetirizine for chronic urticaria (hives) to inform local NHS planning and decision-making

Evidence summary Published July 2014

ESNM68: Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream

Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

Evidence summary Published January 2016

ESNM43: Facial erythema of rosacea: brimonidine tartrate gel

Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making

Evidence summary Published July 2014

Tacrolimus and pimecrolimus for atopic eczema (TA82)

Evidence-based recommendations on non-steroidal tacrolimus and pimecrolimus for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Adalimumab for the treatment of adults with psoriasis (TA146)

Evidence-based recommendations on adalimumab (Humira) for the treatment of adults with plaque psoriasis

Technology appraisal guidance Published June 2008

Infliximab for the treatment of adults with psoriasis (TA134)

Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults

Technology appraisal guidance Published January 2008

ESUOM29: Difficult-to-treat scabies: oral ivermectin

Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making

Evidence summary Published March 2014

Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)

Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer

Medical technologies guidance Published July 2011

ESUOM16: Hyperhidrosis: oral glycopyrronium bromide

Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published July 2013

ESUOM47: Infantile haemangioma: topical timolol

Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making

Evidence summary Published August 2015

Alitretinoin for the treatment of severe chronic hand eczema (TA177)

Evidence-based recommendatrions on alitretinoin (Toctino) for treating severe chronic hand eczema in adults

Technology appraisal guidance Published August 2009

Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy (IPG439)

Evidence-based recommendations on deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy (lipodystrophy/wasting syndrome)

Interventional procedures guidance Published January 2013

Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2017

Accreditation

Processes used to produce guidance and advice that have been accredited by NICE

Published June 2017

Omalizumab for previously treated chronic spontaneous urticaria (TA339)

Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)

Technology appraisal guidance Published June 2015

Food allergy in under 19s

Everything NICE has said on diagnosing and assessing food allergy in children and young people in primary care and community settings in an interactive flowchart

NICE Pathway Published December 2011 Last updated May 2017

Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published September 2017

ESNM66: External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

Apremilast for treating moderate to severe plaque psoriasis (TA419)

Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published November 2016

Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

Evidence-based recommendations on treating obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) for adults, young people and children

Clinical guideline Published November 2005

VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)

Evidence-based recommendations on VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions

Diagnostics guidance Published November 2015

Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults

Technology appraisal guidance Published September 2009 Last updated March 2017

Sunlight exposure: risks and benefits

Everything NICE has said on how to communicate the risks and benefits of natural sunlight exposure in an interactive flowchart

NICE Pathway Published February 2016 Last updated June 2017

Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

Evidence-based recommendations on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Technology appraisal guidance Published June 2016

Frequency of application of topical corticosteroids for atopic eczema (TA81)

Evidence-based recommendations on the frequency of application of topical corticosteroids for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Committee A members

clinical interests are paediatric HIV and paediatric dermatology. He is also the clinical lead for paediatrics. He is an honorary...

Published January 2016

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

Evidence-based recommendations on etanercept (Enbrel) infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis

Technology appraisal guidance Published August 2010

Spondyloarthritis in over 16s: diagnosis and management (NG65)

Evidence-based recommendations on diagnosing and managing spondyloarthritis that is suspected or confirmed in over 16s

NICE guideline Published February 2017 Last updated June 2017

Haematological cancers: improving outcomes (NG47)

Evidence-based recommendations on integrated diagnostics reporting and improving services, staffing and care for people with haematological cancer

NICE guideline Published May 2016

Melanoma

Everything NICE has said assessing and managing melanoma in an interactive flowchart

NICE Pathway Published July 2015 Last updated September 2017

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for treating plaque psoriasis in children and young people

Technology appraisal guidance Published July 2017

Previous NICE Fellows

aims to develop a combined dermatology and oculoplastic tumour service. His aim is to evaluate the NICE guidance relating to eyelid...

Published August 2017

Ustekinumab for treating active psoriatic arthritis (TA340)

Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults

Technology appraisal guidance Published June 2015 Last updated March 2017

MIB25: The Juxta CURES adjustable compression system for treating venous leg ulcers

Advice on the use of the Juxta CURES adjustable compression system for treating venous leg ulcers to aid local decision-making

Medtech innovation briefing Published March 2015

Suspected cancer recognition and referral

Everything NICE has said on suspected cancer, recognition and selection for referral or investigation in primary care in an interactive flowchart

NICE Pathway Published June 2015 Last updated July 2017